CYP2D6 copy number distribution in the US population

被引：34

作者：

Beoris, Michelle ^{[1
]}

Wilson, Jean Amos ^{[1
]}

Garces, Jorge A. ^{[1
]}

Lukowiak, Andrew A. ^{[1
]}

机构：

[1] AltheaDx, 10578 Sci Ctr Dr, San Diego, CA 92121 USA

来源：

PHARMACOGENETICS AND GENOMICS | 2016年 / 26卷 / 02期

关键词：

codeine; gene duplication; cytochrome P450 CYP2D6; gene deletion; pharmacogenetics; CYTOCHROME-P450; 2D6; CYP2C19; GENOTYPES; GUIDELINE; GENETICS; UPDATE;

D O I：

10.1097/FPC.0000000000000188

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

The cytochrome P450 2D6 (CYP2D6) gene is perhaps the most well characterized gene involved in drug metabolism and is known to have both gene duplication and deletion variants that are inheritable and stable. In a set of over 30 000 deidentified clinical samples we found that 12.6% of all patients tested had zero, one, or three or more copies of the CYP2D6 gene. On the basis of the combined frequency and impact of these variants, we believe that CYP2D6 copy number variation may account for the single most impactful genetic anomaly as it relates to pharmacogenetic directed therapies.

引用

页码：96 / 99

页数：4

共 9 条

[1]

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update [J].

Crews, K. R. ;

Gaedigk, A. ;

Dunnenberger, H. M. ;

Leeder, J. S. ;

Klein, T. E. ;

Caudle, K. E. ;

Haidar, C. E. ;

Shen, D. D. ;

Callaghan, J. T. ;

Sadhasivam, S. ;

Prows, C. A. ;

Kharasch, E. D. ;

Skaar, T. C. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (04) :376-382

[2]

The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype [J].

Gaedigk, A. ;

Simon, S. D. ;

Pearce, R. E. ;

Bradford, L. D. ;

Kennedy, M. J. ;

Leeder, J. S. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) :234-242

[3]

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors [J].

Hicks, J. K. ;

Bishop, J. R. ;

Sangkuhl, K. ;

Mueller, D. J. ;

Ji, Y. ;

Leckband, S. G. ;

Leeder, J. S. ;

Graham, R. L. ;

Chiulli, D. L. ;

LLerena, A. ;

Skaar, T. C. ;

Scott, S. A. ;

Stingl, J. C. ;

Klein, T. E. ;

Caudle, K. E. ;

Gaedigk, A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (02) :127-134

[4]

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants [J].

Hicks, J. K. ;

Swen, J. J. ;

Thorn, C. F. ;

Sangkuhl, K. ;

Kharasch, E. D. ;

Ellingrod, V. L. ;

Skaar, T. C. ;

Mueller, D. J. ;

Gaedigk, A. ;

Stingl, J. C. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (05) :402-408

[5]

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity [J].

Ingelman-Sundberg, M .

PHARMACOGENOMICS JOURNAL, 2005, 5 (01) :6-13

[6]

Pharmacogenomics of CYP2D6: Molecular Genetics, Interethnic Differences and Clinical Importance [J].

Teh, Lay Kek ;

Bertilsson, Leif .

DRUG METABOLISM AND PHARMACOKINETICS, 2012, 27 (01) :55-67

[7]

Copy number variations' effect on drug response still overlooked [J].

Willyard, Cassandra .

NATURE MEDICINE, 2015, 21 (03) :206-206

[8]

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry [J].

Zanger, UM ;

Raimundo, S ;

Eichelbaum, M .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 369 (01) :23-37

[9]

Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance Part II [J].

Zhou, Shu-Feng .

CLINICAL PHARMACOKINETICS, 2009, 48 (12) :761-804

← 1 →